NATCO Pharma Limited issued a formal response dated February 25, 2026, regarding unusual trading volume in its shares, referencing a query from the BSE. The company affirmed that it has fulfilled all required regulatory disclosures concerning price-sensitive information that could influence trading activity. NATCO asserts that the observed increase in share volume is purely a result of market-driven factors and prevailing market conditions.
Official Response to Stock Volume Inquiry
On February 25, 2026, NATCO Pharma Limited provided a formal response to a query from the BSE Limited concerning the recent unusual movement in the volume of the company’s shares (Scrip Code: 524816). The communication referenced a specific letter from the exchange regarding this volume surge.
Compliance and Market Driving Factors
NATCO confirmed that the organization has adhered strictly to all mandates under Regulation 30 of the relevant corporate disclosure regulations. This adherence confirms that the company has disclosed every material or price-sensitive piece of information bearing upon its operations or performance. Crucially, the management stated that it has not withheld any information that, in its view, would affect the trading behavior of its shares.
Therefore, the company concluded that the elevated trading volume experienced recently is a direct consequence of purely market-driven forces and general market conditions, rather than any undisclosed internal event.
Conclusion
The information was submitted for the regulator’s records and information, signed by Ch. Venkat Ramesh, Company Secretary & Compliance Officer.
Source: BSE
